How many drugs treat Malignant lymphoma?

Drug Landscape tracks 8 marketed treatments for Malignant lymphoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/malignant-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Malignant lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant lymphoma (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Mozobil	plerixafor	Sanofi	Hematopoietic Stem Cell Mobilizer [EPC]	C-C chemokine receptor type 2	2008-01-01
Cytoxan (Lyophilized)	cyclophosphamide	Baxter	Alkylating agent	Tumor cell DNA	1959-01-01
Busulfex	busulfan	Waylis	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1954-01-01
Mozobil	Mozobil	University of Washington		Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2
Cyclophosphamid	Cyclophosphamid	Zhejiang University		Cytochrome P450 3A4
busulfex	busulfex	Dana-Farber Cancer Institute		Matrix metalloproteinase-9
Busilvex	Busilvex	medac GmbH		Matrix metalloproteinase-9
Busulphan	Busulphan	University of Birmingham		Matrix metalloproteinase-9

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Baxter · 2 drugs in Malignant lymphoma
Dana-Farber Cancer Institute · 1 drug in Malignant lymphoma
Sanofi · 1 drug in Malignant lymphoma
University of Birmingham · 1 drug in Malignant lymphoma
University of Washington · 1 drug in Malignant lymphoma
Waylis · 1 drug in Malignant lymphoma
Zhejiang University · 1 drug in Malignant lymphoma
medac GmbH · 1 drug in Malignant lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant lymphoma:

Cite this brief

Drug Landscape (2026). Malignant lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-lymphoma. Accessed 2026-06-10.

Malignant lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing